Identifying Plausible Genetic Models Based on Association and Linkage Results: Application to Type 2 Diabetes by Guan, Weihua et al.
Genetic Epidemiology 36 : 820–828 (2012)
Identifying Plausible Genetic Models Based on Association and
Linkage Results: Application to Type 2 Diabetes
Weihua Guan,1∗ Michael Boehnke,2 Anna Pluzhnikov,3 Nancy J. Cox,3 and Laura J. Scott2
1Division of Biostatistics School of Public Health, University of Minnesota, Minneapolis, Minnesota
2Department of Biostatistics and Center for Statistical Genetics School of Public Health, University of Michigan, Ann Arbor, Michigan
3Section of Genetic Medicine Department of Medicine, University of Chicago, Chicago, Illinois
When planning resequencing studies for complex diseases, previous association and linkage studies can constrain the range
of plausible genetic models for a given locus. Here, we explore the combinations of causal risk allele frequency (RAFC)
and genotype relative risk (GRRC) consistent with no or limited evidence for affected sibling pair (ASP) linkage and strong
evidence for case-control association. We find that significant evidence for case-control association combined with no or
moderate evidence for ASP linkage can define a lower bound for the plausible RAFC. Using data from large type 2 diabetes
(T2D) linkage and genome-wide association study meta-analyses, we find that under reasonable model assumptions, 23 of 36
autosomal T2D risk loci are unlikely to be due to causal variants with combined RAFC < 0.005, and four of the 23 are unlikely
to be due to causal variants with combined RAFC < 0.05. Genet. Epidemiol. 36:820–828, 2012. C© 2012 Wiley Periodicals, Inc.
Key words: gene mapping; genetics; genetic structure; complex diseases
Supporting Information is available in the online issue at wileyonlinelibrary.com.
Contract grant sponsor: National Institutes of Health; Contract grant numbers: HG000376; DK062370.
∗Correspondence to: Weihua Guan, Division of Biostatistics, School of Public Health, University of Minnesota, A460 Mayo Building, MMC
303, 420 Delaware St. S.E., Minneapolis, MN 55455. E-mail: wguan@umn.edu
Received 24 January 2012; Revised 19 June 2012; Accepted 20 June 2012
Published online 3 August 2012 in Wiley Online Library (wileyonlinelibrary.com/journal/gepi).
DOI: 10.1002/gepi.21668
INTRODUCTION
Genome-wide association studies (GWAS) allow in-
vestigators to test for disease or trait (henceforward
disease) association with common single nucleotide poly-
morphisms (SNPs) throughout the human genome. To-
day’s commercial GWAS platforms, when combined with
genotype imputation [e.g., Li et al., 2010; Marchini et al.,
2007], typically cover 80–90% of known common genetic
variants (minor allele frequency (MAF) > 0.05). In recent
years, GWAS have been conducted for many diseases [see
http://www.genome.gov/gwastudies/]. The combined ef-
fects of associated variants often explain only a small pro-
portion of the disease genetic variation [Manolio et al., 2009].
Results to date suggest that most common variants associ-
ated with complex diseases have modest effect on disease
risk. Less common (0.005 < MAF < 0.05) and rare (MAF <
0.005) variants have not yet been studied extensively and
may (or may not) have larger effect sizes. With the recent
advances in sequencing technology, it has become feasible
to identify and genotype these variants. While multiple the-
oretical and data-driven approaches have examined genetic
architecture of complex human diseases and traits [Ander-
son et al., 2011; Dickson et al., 2010; Lee et al., 2011; Pritchard
and Cox, 2002; Purcell et al., 2009; Reich and Lander, 2001;
Risch and Merikangus, 2001; Wray et al., 2011], our knowl-
edge of their underlying architecture remains limited. Cur-
rent and planned large-scale sequencing studies seek to ad-
dress this issue.
Previous complex disease linkage studies generally re-
ported limited evidence for linkage, and even in studies
with strong linkage signals, most of the genome provides no
evidence for linkage. These negative linkage results should
limit the range of plausible effect sizes for disease risk vari-
ants and/or the cumulative frequency of risk variants. Sim-
ilarly, evidence (or lack of evidence) for association in a
region of interest should also limit the range of plausible
models for these risk variant(s).
Existing association and/or linkage results together with
simulations have been used by multiple groups to explore
the likely genetic architectures underlying complex dis-
eases. Purcell et al. [2009] showed that rare or less com-
mon causal variants are unlikely to be the sole explanation
of schizophrenia genetic variation based on simulations to
identify models that are consistent with GWAS results and
heritability estimates. Similarly, the work of Wray et al.
[2011] suggests that rare variants are unlikely to underlie
a large proportion of GWAS associations as they would ex-
plain >100% of the heritability. Dickson et al. [2010] argued
that many common variants identified in GWAS could re-
flect multiple less common (0.005 < MAF < 0.02) causal
variants in high linkage disequilibrium (LD); using the
same models, Anderson et al. [2010] concluded that rare
variants were unlikely to underlie most GWAS-associated
variants. Both studies provided graphical representations of
the power of affected sibling pair (ASP) linkage (with An-
derson et al. assuming a much larger linkage sample) and
SNP disease association under limited number of models.
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However, they did not provide a quantitative way to define
plausible models (minimum RAFC, maximum GRRC) for
specified disease loci given the results of existing linkage
and association studies.
In this paper, we seek to identify the plausible range of
genetic models, in terms of genotype relative risk (GRRC)
and risk allele frequency (RAFC), consistent with rare or
less common causal variant(s) underlying a given disease
association. We consider scenarios in which no or modest
evidence for ASP linkage is reported, and/or significant ev-
idence for association is reported. To do so, we calculate the
power to detect ASP linkage and/or case-control associa-
tion and summarize the range of genetic models that ap-
pears plausible given results from available linkage and/or
association studies. Our results show that for each risk al-
lele frequency RAFC, the effect sizes GRRC of causal variants
are constrained by ASP linkage or association results. When
significant evidence for association is combined with no or
modest ASP linkage evidence in the same chromosomal re-
gion, causal variants with small RAFC can also be identified
as implausible. In our calculations, we assume that a sin-
gle causal variant underlies a common variant association,
but our results can be extended to include multiple rare
or less frequent tightly linked causal variants. Combining
available T2D SNP association [Dupuis et al., 2010; Qi et al.,
2010; Voight et al., 2010; Zeggini et al., 2008] and linkage
[Guan et al., 2008; unpublished data] results suggest that at
least 23 of 36 autosomal T2D loci are unlikely due to single
or cumulatively rare disease variants.
METHODS
To understand the genetic architecture underlying a com-
plex disease, we seek to identify a set of models that are
plausible given prior results from ASP linkage and/or case-
control association studies. We parameterize these models
by the genotype relative risk (GRRC) and risk allele fre-
quency (RAFC) of a causal variant C. We assume that the
causal allele is the minor allele and is dominant, that the
effects of the disease loci combine multiplicatively to deter-
mine disease risk, and that we have genotyped a sufficiently
dense set of linkage markers that the identity by descent
(IBD) relationship for the ASP can be observed. We assume
a disease prevalence of 10%, and a standardized LD coef-
ficient D′ = 0.6, 0.8, or 1 between the causal variant C and
a nearby genotyped variant M. We discuss the impact of
these assumptions in the section Discussion.
POWER TO DETECT LINKAGE IN AN ASP
STUDY
Let Ni be the number of ASPs sharing i = 0, 1, or 2 alleles
IBD at the causal locus. Although the specified penetrance
model at the causal locus is dominant, we calculate the usual
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Given our assumption of a multiplicative relationship
between causal loci, power to detect linkage using ASPs
depends only on the locus-specific relative risks [Risch,
1990].
We calculate power to detect linkage for studies of N =
500, 1,000, and 5,000 ASPs and causal variant RAFC from
0.001 to 0.05. We report results for MLS threshold values
of 0 and 1, representing no or modest evidence for linkage,
respectively. For a given RAFC, we determine the value of
GRRC that results in 95% power to obtain MLS > 0 or 1, using
the false position method [Press et al., 1992], an algorithm
for root finding.
POWER TO DETECT ASSOCIATION IN A
CASE-CONTROL STUDY
We assume a GWAS with n cases and n controls. Let C
be a causal variant in LD with a genotyped marker M. Let
RAFM be the risk allele frequency at M and gC and gM be the
genotypes at C and M, coded as the number of risk alleles
(0, 1, or 2). Given RAFC, RAFM, and D′, we calculate the
conditional genotype probability P(gC | gM). For a specified
genetic model and disease prevalence, we can then compute


























which will determine the power of association test at a given
locus. Under the dominant model, P(Y = 1 | gC = 2) = P(Y
= 1 | gC = 1) = GRRC × P(Y = 1 | gC = 0). We exclude
models with large GRRC for which P(Y | gC) > 1 for any
genotype gC. Here, we assume a single causal variant C,
but our results can easily be extended to multiple causal
variants in the same region (see section Discussion).
Although the specified penetrance model, P(Y | gC),
is dominant, we test for disease association at M using
the additive-model version of the Cochran-Armitage trend
test, as is typical in analysis of GWAS data. We calculate
the power of the trend test by estimating the variance of
the test statistic under the alternative hypothesis [Freidlin
et al., 2002].
We calculate power to detect association assuming n =
1,000, 10,000, and 50,000 cases and the same number of
controls and causal variant C and genotyped variant M fre-
quencies 0.001 ≤ RAFC ≤ 0.05 and 0.05 ≤ RAFM ≤ 0.95.
Given RAFC and RAFM, we calculate the GRRC value that
results in 5% power to detect disease association at M at
genome-wide significance level  = 5 × 10−8 using the false
position method.
LD IN 1000 GENOMES PROJECT DATA
To assess the plausibility of our assumption that there
exists a GWAS marker M in strong LD with the causal
variant C, we evaluate the range of LD values between
less common (0.005 < MAF < 0.05) and common (MAF
> 0.05) chromosome 1 variants identified in 283 Euro-
pean samples in the 1000 Genomes Project August 2010
release (http://www.1000genomes.org/). We first examine
the distribution of maximum r2 values for each less common
variant between the less common variant-common variant
pairs, and then examine the D′ values between the less com-
mon variant and common variant with the maximum r2. We
limit our attention to common variants within a 1000 SNP
(∼250 kb) window of each less common variant.
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TABLE I. T2D susceptibility loci detected with common variants. RAFC is a lower bound at which there is 5% power to
detect association at observed P-value at marker M in a GWAS of the given effective sample size, and 95% power to
detect linkage at the observed MLS value given 4,200 ASPs
Nearby Effective RAFM Minimum Maximum
SNP gene(s) OR P-value MLS sample size in controls RAFC GRRC Referencea
rs1531343b HMGA2 1.08 1.1 × 10−4 1.00 68,314 0.10 <0.001 >4.1 Voight et al. [2010]
rs4607517c GCK 1.07 5.0 × 10−8 0.88 94,370 0.16 <0.001 >7.3 Dupuis et al. [2010]
rs8042680b PRC1 1.06 1.6 × 10−6 0.82 79,246 0.22 <0.001 >8.1 Voight et al. [2010]
rs10923931b NOTCH2 1.11 1.9 × 10−3 0.00 32,514 0.11 <0.001 >8.5 Zeggini et al. [2008]
rs7961581b TSPAN8,LGR5 1.09 4.3 × 10−5 1.22 31,364 0.27 <0.001 >9.8 Zeggini et al. [2008]
rs12779790b CDC123, CAMK1D 1.09 1.5 × 10−4 0.00 31,364 0.18 0.001 6.2 Zeggini et al. [2008]
rs4457053b ZBED3 1.07 2.7 × 10−7 0.06 67,214 0.26 0.002 6.0 Voight et al. [2010]
rs896854b TP53INP1 1.05 2.2 × 10−5 0.05 67,012 0.48 0.003 5.1 Voight et al. [2010]
rs11634397b ZFAND6 1.05 1.2 × 10−5 0.69 79,246 0.60 0.003 6.5 Voight et al. [2010]
rs10830963c MTNR1B 1.09 8.0 × 10−13 0.14 94,370 0.23 0.004 4.9 Dupuis et al. [2010]
rs4607103b ADAMTS9 1.06 3.5 × 10−3 0.24 31,364 0.76 0.004 5.0 Zeggini et al. [2008]
rs972283b KLF14 1.06 6.4 × 10−6 0.35 56,763 0.55 0.004 5.2 Voight et al. [2010]
rs2191349c DGKB/TMEM195 1.06 1.1 × 10−8 0.74 94,370 0.52 0.004 5.9 Dupuis et al. [2010]
rs864745b JAZF1 1.10 1.3 × 10−7 1.09 31,364 0.50 0.007 4.8 Zeggini et al. [2008]
rs7957197b HNF1A 1.05 4.6 × 10−4 0.05 67,751 0.85 0.009 3.4 Voight et al. [2010]
rs780094c GCKR 1.06 1.3 × 10−9 0.27 94,370 0.62 0.009 3.9 Dupuis et al. [2010]
rs340874c PROX1 1.07 7.2 × 10−10 0.00 94,370 0.52 0.010 3.0 Dupuis et al. [2010]
rs5215d KCNJ11 1.09 1.6 × 10−5 0.01 22,044 0.45 0.010 3.2 Voight et al. [2010]
rs243021b BCL11A 1.08 6.2 × 10−11 0.09 64,343 0.46 0.010 3.5 Voight et al. [2010]
rs1470579d IGF2BP2 1.14 2.2 × 10−9 0.20 22,044 0.30 0.010 3.6 Voight et al. [2010]
rs231362b KCNQ1 1.07 3.2 × 10−9 0.00 73,750 0.52 0.011 3.1 Voight et al. [2010]
rs9939609d FTO 1.12 8.7 × 10−8 0.14 22,044 0.38 0.011 3.4 Voight et al. [2010]
rs4430796b HNF1B 1.12 1.6 × 10−4 0.00 13,930 0.51 0.014 2.8 Voight et al. [2010]
rs7593730b RBMS1 1.09 9.1 × 10−5 0.01 32,172 0.77 0.021 2.5 Qi et al. [2010]
rs10010131b WFS1 1.11 4.6 × 10−7 0.05 22,044 0.60 0.026 2.5 Voight et al. [2010]
rs13292136b CHCHD9 1.08 2.4 × 10−4 0.00 79,246 0.93 0.029 2.3 Voight et al. [2010]
rs7578597b THADA 1.12 9.2 × 10−5 0.18 32,514 0.90 0.038 2.5 Zeggini et al. [2008]
rs7754840d CDKAL1 1.18 3.1 × 10−15 0.00 22,044 0.36 0.043 2.1 Voight et al. [2010]
rs7578326b IRS1 1.10 2.2 × 10−15 0.00 67,701 0.64 0.043 2.1 Voight et al. [2010]
rs13266634b SLC30A8 1.15 1.5 × 10−8 0.11 20,675 0.68 0.048 2.3 Voight et al. [2010]
rs1801282d PPARG 1.15 8.0 × 10−6 0.11 22,044 0.82 0.048 2.3 Voight et al. [2010]
rs1111875d HHEX 1.17 9.1 × 10−15 0.18 22,044 0.52 0.049 2.3 Voight et al. [2010]
rs7903146d TCF7L2 1.40 2.2 × 10−51 0.08 22,044 0.18 0.059 2.1 Voight et al. [2010]
rs11708067c ADCY5 1.12 9.9 × 10−21 0.00 94,370 0.78 0.090 1.8 Dupuis et al. [2010]
rs1552224b CENTD2 1.14 3.2 × 10−18 0.09 79,246 0.88 0.130 1.9 Voight et al. [2010]
rs10811661d CDKN2A/B 1.19 1.4 × 10−10 0.00 22,044 0.85 0.217 1.7 Voight et al. [2010]
aEach locus had a single or multistage P-value < 5×10−8. Some T2D-associated loci were reported in multiple references. We use results from
the largest available follow-up cohort when possible (28 variants), or if not, from the largest available GWAS (which also contain the initial
discovery samples) and list the estimated OR, P-values, and the effective sample sizes correspondingly.
bFollow-up sample.
cTop loci from a GWAS for fasting glucose were tested for association with T2D, equivalent to a candidate gene study.
dGWAS meta-analysis including the discovery samples.
APPLICATION TO TYPE 2 DIABETES (T2D)
We illustrate how existing ASP linkage and case-control
GWAS results provide information on plausible models for
variants underlying complex diseases using results for T2D.
We carried out a joint analysis of data from 23 linkage stud-
ies as part of the International Type 2 Diabetes Linkage
Analysis Consortium [Guan et al., 2008; unpublished data].
Here, we restrict our attention to an ASP linkage analysis
of 6,552 individuals in 2,315 families of European ances-
try, equivalent to ∼4,200 ASPs, using the approximation
that m-affected siblings correspond approximately to m-1-
independent ASPs [Hodge 1984]. In this study, the largest
MLS was approximately 2.2, and for approximately 54% of
the genome, MLS = 0. For T2D linkage results, we calculate
power as above based on 4,200 ASPs, using the observed
MLS from the linkage study at that location as the MLS
threshold for power calculations (unpublished data).
Published European ancestry association studies of T2D
have identified 36 autosomal T2D loci using standard case-
control analysis (Table I), most from GWAS. To place the
T2D linkage and association results on the same map,
we linearly interpolate positions for the 36 T2D-associated
variants onto a genetic map of 2,164 microsatellite markers
from our linkage analysis based on their physical positions
Genet. Epidemiol.
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in NCBI build 36.1. We identify the plausible genetic models
at these 36 loci given the observed linkage and association
results. At each locus, we calculate power to detect linkage
and association as above. To minimize possible overesti-
mation of genetic effect owing to the “winner’s curse” (for
example Zöllner and Pritchard, 2007), we use results from
the largest available follow-up cohort when possible (28
variants), or alternatively from the largest available GWAS
(eight variants where discovery samples are ∼40% of the to-
tal sample). For T2D association results, we calculate power
as described above, using the sum of the effective numbers
of genotyped cases and controls in each study as sample
size, the observed RAFM in controls as the population al-
lele frequency, and the observed association P-value as the
significance threshold.
RESULTS
Here, we address the range of plausible model parameters
(RAFC and GRRC) for rare or less common causal variants
(RAFC < 0.05), assuming a dominant genetic model for a
genomic region given results from prior linkage and/or
(common variant) association studies. To do so, we compute
the power to detect linkage and/or association as a function
of genetic model.
RANGE OF PLAUSIBLE MODELS GIVEN NO OR
MODEST EVIDENCE FOR LINKAGE
Complex disease linkage studies generally reveal no
(MLS = 0) or modest (MLS ≤ 1) evidence for linkage
for most of the genome. We explore the range of genetic
model parameters consistent with these observations. Fig-
ure 1 displays values for GRRC that result in 95% power
to observe MLS > 0 or MLS > 1 given analysis of N
= 500–5,000 ASPs as a function of risk allele frequency
RAFC.
Assuming a causal variant exists, models (RAFC and
GRRC) above the power curves in Figure 1A have ≥ 95%
probability of showing at least some evidence for linkage
(MLS > 0), and therefore such variants are unlikely to be
present in a region with no evidence of linkage (MLS = 0).
For example, given N = 5,000 ASPs, a causal variant with
RAFC = 0.01 and GRRC > 2.9 or with RAFC = 0.05 and
GRRC > 1.9 has ≥ 95% power to achieve MLS > 0, suggest-
ing these models are unlikely at a locus with no evidence
for linkage. Similarly, given N = 5,000 ASPs and MLS =
1, a causal variant with RAFC = 0.01 is unlikely to have
GRRC > 3.9 (Figure 1B). As expected, all else being equal,
the larger the linkage study sample, the more restricted the
set of plausible models.
RANGE OF PLAUSIBLE MODELS GIVEN
SIGNIFICANT EVIDENCE FOR ASSOCIATION
Genome-wide significant associations with common
SNPs have been reported for many common diseases
(http://www.genome.gov/gwastudies/). We explore the
range of models (RAFC and GRRC) for which a disease
association could be explained by a rare or less common
causal variant(s). Figure 2 shows values of GRRC that lead
to 5% power to detect association (P < 5×10−8) at SNP
M with RAFM = 0.05–0.95, assuming a study of n cases
Fig. 1. Genotype relative risks at causal variant C (GRRC) that
result in 95% power to detect some evidence for linkage at MLS
> 0 and MLS > 1.
Fig. 2. Genotype relative risks at causal variant C (GRRC) that
result in 5% power to detect association (P < 5×10−8) at geno-
typed variant M using n cases and n controls. We assume disease
prevalence 10% and D′ = 1 between M and C.
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and n controls (n = 1,000–50,000) and D′ = 1 between the
genotyped variant M and causal variant C. Models be-
low the power curves have < 5% probability of achiev-
ing such evidence for association for a genotyped vari-
ant M in high LD (D′ = 1) with the causal variant C. We
have chosen 5% power so that a causal variant C with a
small chance of underlying a common variant M association
(based on GRRC and RAFC) will be considered as plausible,
given the current 10s to 100s of associated loci for common
diseases.
For example, given n = 10,000 cases and 10,000 controls, a
causal variant with RAFC = 0.01 and GRRC < 3.4 has < 5%
power to achieve genome-wide significance (P < 5×10−8) at
a genotyped variant M (D′ = 1) with RAFM = 0.3, suggest-
ing these models are unlikely to explain the corresponding
association at M. Holding the significance level and sample
size constant, a marker with larger GRRM will yield a more
limited set of plausible genetic models (Figure 2). We also
estimate the plausible range of models assuming D′ = 0.8
or 0.6 between the causal variant C and genotyped variant
M (Supporting information Figure 1). For a given signifi-
cance level and RAFC, a causal variant with D′ < 1 requires
larger GRRC to reach the same power as a causal variant
with D′ = 1, resulting in a more limited set of plausible
models.
RANGE OF PLAUSIBLE MODELS GIVEN
RESULTS FROM ASSOCIATION AND LINKAGE
STUDIES
For complex diseases for which both linkage and associ-
ation scans have been carried out, we observe no evidence
for linkage (MLS = 0) in most regions of the genome, and
some of these regions may contain genome-wide significant
association results (P < 5×10−8). Figure 3A shows values of
GRRC that result in 5% power to detect association (P <
5×10−8) at genotyped variant M given n = 10,000 cases
and n = 10,000 controls, and 95% power to detect at least
some evidence for linkage (MLS > 0) given 1,000 ASPs, as a
function of RAFC, assuming D′ = 1 between the causal and
common GWAS variant. The models above the 5% power
curve for association but below the 95% power curve for
linkage (shaded area in Figure 3) are consistent with strong
evidence for association (P < 5×10−8) and no evidence for
linkage (MLS = 0) at the corresponding position. Here, sig-
nificant evidence for association (P = 5×10−8) and no evi-
dence for linkage (MLS = 0) suggest RAFC > 0.014.
Figure 3B and C shows values of GRRC for D′ = 0.8 or
0.6 as a function of RAFC that result in 5% power to detect
association (P < 5 × 10−8) at genotyped variant M given
n = 10,000 cases and n = 10,000 controls, and 95% power
to detect some evidence for linkage (MLS > 0) given 1,000
ASPs. Again the shaded areas in the figures are consistent
with strong evidence for association (P < 5 × 10−8) and
no evidence for linkage (MLS = 0) at the corresponding
position. In these scenarios, the range of plausible RAFC
values is more extensive than those for D′ = 1. For example,
significant evidence for association (P = 5 × 10−8) and no
evidence for linkage (MLS = 0) suggest RAFC > 0.043 for
D′ = 0.6 and RAFC > 0.022 for D′ = 0.8 compared to RAFC
> 0.014 for D′ = 1.
Fig. 3. Genotype relative risks at causal variant C (GRRC) that
result in 95% power to detect some evidence for linkage (MLS
> 0) using 1,000 ASPs and 5% power to detect association (P <
5×10−8) at genotyped variant M with RAFM = 0.5 using n = 10,000
cases and n = 10,000 controls. The shaded area is the estimated
range of plausible models. We assume disease prevalence 10%
and D′ = 1, 0.8, and 0.6 between M and C.
OBSERVED D′ AND r2 IN 1000 GENOMES DATA
In practice, the LD between an unidentified causal
variant C and a common associated variant M is
unknown. To explore the LD between common and
less common variants, we examine sequence data on
283 European subjects from the 1000 Genomes Project
(http://www.1000genomes.org/). We calculate D′ and r2
between 268,287 less common SNPs (0.005 < MAF < 0.05)
and 423,648 common SNPs (MAF > 0.05) on chromosome 1,
limiting our attention to pairs of SNPs within approximately
250 kb of each other.
Given a causal variant in the region, the most strongly
associated GWAS variant is expected to be the common
GWAS variant in highest r2 with the causal variant. For
every less common 1000 Genomes Project SNP, we identify
the common 1000 Genomes SNP in highest r2. We find that
the best common pairing SNPs usually have RAFM < 0.3
(Figure 4). We also find that 49% of the maximum r2 SNP
pairs have D′ = 1, 67% have D′ ≥ 0.8, and 88% have D′ ≥
0.6, which suggests that an assumption of D′ = 1 between
the common associated variant and the causal SNP would
cause the bounds on RAFC to be too wide about half the
time.
Genet. Epidemiol.
Identifying Genetic Models Based on Association and Linkage Results 825
Fig. 4. Frequency distribution of best pairing alleles for less com-
mon (0.005 < MAF < 0.05) variants in 1000 Genome Project se-
quence data (August 2010 release). We define the best pairing
alleles as having the highest r2 but lowest minor allele frequency.
EXAMPLE: T2D
Many linkage and association studies have been carried
out for T2D. Perhaps the largest single linkage study was
one based on the equivalent of 4,200 ASPs with European
ancestry carried out by the International Type 2 Diabetes
Linkage Analysis Consortium [Guan et al. 2008; unpub-
lished data]. This study found no genome-wide significant
evidence for linkage, and a maximum MLS genome-wide of
approximately 2.2. In contrast, published GWAS and candi-
date gene association studies in European ancestry samples
(through October 2011) have reported genome-wide signif-
icant association (P < 5×10−8) at 36 autosomal loci using
the standard case-control test (Table I, Figure 5). For these
36 T2D loci, we observe that higher MLS are modestly cor-
related with lower RAFM (r = –0.31, P = 0.06), suggesting
that at least some of the linkage peaks may be detecting rare
or less common underlying causal variants (Supporting in-
formation Figure 2). Likewise, 29 of the 36 T2D-associated
SNPs are at positions with MLS > 0 (P-value = 0.0002 com-
pared to an expectation of 50%, or P-value = 0.0009 com-
pared to the observed proportion of 54%).
Using the observed T2D linkage and association results,
we estimate the range of plausible RAFC (Table I) assuming
D′ = 1 between the causal variant and a common GWAS
variant. Thirteen association signals could plausibly be ex-
plained by a very wide range of risk allele frequencies RAFC
including RAFC < 0.005. Four of the five loci with the small-
est plausible combined RAFC (< 0.001) have modest evi-
dence for linkage (0.82 < MLS < 1.22) and association RAFM
< 0.30. For the 23 other association signals, the associations
are unlikely to be explained by one or more causal vari-
ants with combined RAFC < 0.005, and for four of these
(TCF7L2, ADCY5, CENTD2, CDKN2A/B), combined RAFC
was less than 0.05 is unlikely. In these regions, a GWAS
study with a dense marker set with good coverage for vari-
ants with MAF > 0.01 might well result in the causal variant
being genotyped or tagged by genotyped markers.
DISCUSSION
We have sought to determine the range of disease models
consistent with existing linkage and/or association results.
Specifically, we have focused on determining the minimum
plausible risk allele frequency RAFC and corresponding
genotype relative risk GRRC for variants at a given locus
assuming a single causal variant underlies an association
signal. Our results show that a linkage study alone or an as-
sociation study alone can restrict the plausible magnitude of
GRRC, while all RAFC in the range we consider remain pos-
sible. Joint consideration of linkage and association results
can further reduce the set of plausible models. In particular,
at loci with significant evidence for association and no evi-
dence for linkage, one or more causal variant(s) with a low
summed risk allele frequency may be implausible.
To calculate the power for linkage and association tests,
we have made several assumptions. First, we assume that
only a single causal variant C exists in the region of in-
terest in our power calculation. If multiple causal variants
are present within the region, the linkage signal will reflect
the combined effects of all causal variants. Using linkage
results alone, our estimates of the causal allele frequency
would approximately correspond to the sum of the risk al-
lele frequencies; individual causal variants could be much
rarer. In contrast, the impact of multiple variants on a given
common association signal is more complex as the observed
signal will only reflect the causal variants in LD with the
tested common allele. Wang et al. [2010] and Dickson et al.
[2010] have described scenarios where multiple rare causal
variants could contribute to an apparent common variant
association, a phenomenon they termed “synthetic associa-
tion” (Wang et al. [2010]). If all causal alleles occur on hap-
lotypes with the associated common allele, the synthetic
causal marker will have a D′ = 1 with the common as-
sociated marker. In contrast, if the causal alleles occur on
haplotypes with and without the associated allele, the syn-
thetic causal marker will have a D′ < 1 with the common
associated marker. These two scenarios described above are
analogous to the ones shown in Figure 3A and B. If P-value
= 5 × 10−8 is observed for a common marker and the un-
derlying synthetic causal marker has a D′ = 0.8 with the
common marker, analysis assuming a D′ = 1 (Figure 3A)
Fig. 5. T2D linkage maximum LOD scores (MLS) from the International Type 2 Diabetes Linkage Analysis Consortium (families of
European origin) (solid line) and significant T2D associations from various sources (Table I) (diamonds).
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will yield a lower estimate of the minimum plausible cu-
mulative RAFC than analysis under the true model of D′
= 0.8 (Figure 3B) (RAFC of 0.014 vs. 0.022 in this scenario).
Thus, as in the case of a single causal marker, we will un-
derestimate the lower bound of RAFC assuming D′ = 1.
Estimates of minimum plausible cumulative RAFC for mul-
tiple causal variants under different assumptions of D′ can
be used to construct more realistic simulations of multiple
rare variants RAFC and GRRC. This will aid in the estima-
tion of the power of burden tests [e.g. Li and Leal, 2008] for
given regions.
Second, we assume a dominant model at each disease
locus. Since we focus on models with uncommon or rare
risk variants, risk allele homozygotes are rare, and so dom-
inant, additive, and multiplicative models are essentially
equivalent. A recessive model would result in very rare
homozygotes and is not considered. Third, we assume the
minor allele of variant C is causal. If instead the minor al-
lele is protective, associations detected with high-frequency
RAFM might be inconsistent with rare risk causal variants
but consistent with rare protective variants. Fourth, for link-
age, we assume fully informative markers. If the markers
are not fully informative, our estimation results would give
a smaller range of plausible models (higher RAFC and lower
GRRC). All our assumptions, except for the assumptions of
known IBD in linkage studies and no winner’s curse for the
association results (see below), are conservative in the sense
that they should result in less strict bounds on our model
parameters: the minimum plausible RAFC would be higher
and/or the maximum plausible GRRC would be lower if the
assumptions are violated.
We explore plausible models for 36 T2D variants identi-
fied by large-scale association studies in European ancestry
populations in combination with results from a T2D link-
age study based on the equivalent of approximately 4,200
ASPs. Our results suggest that 23 of the 36 association sig-
nals are unlikely to have been caused by causal variants
with combined RAFC < 0.005, and four of these are un-
likely to have been caused by causal variants with com-
bined RAFC < 0.05. Multiple assumptions underlie these
results. We assume that D′ = 1 between the causal variant
and the associated variant. This assumption will yield the
widest range of plausible models, as it assumes that all of
the causal alleles are on the same haplotype as the common
risk allele. In the 1000 Genomes Project data, 51% of the
maximum r2 variant pairs have D′ < 1 so our estimates for
the plausible range of models may be too wide for these
loci. For example, for the CDC123/CAMK1D locus the mini-
mum plausible RAFC is 0.001 with D′ = 1 and 0.004 for D′ =
0.6. The majority of the significance thresholds used in our
calculations are based on results from follow-up samples.
However, for eight variants the discovery samples make up
approximately 40% of the effective association sample size
and our results could be impacted by the “winner’s curse.”
This could cause overestimation of the strength of the as-
sociation, and thus our estimate of the minimum plausible
RAFC may be too high. This concern is balanced by our use
of a fairly conservative 5% power to detect the observed
association that may have caused us to underestimate the
RAFC and overestimate GRRC for some loci. To explore the
sensitivity of the minimum RAFC and maximum GRRC es-
timates to the set power thresholds, we repeated our anal-
ysis using 50% power for association (i.e. assuming the ob-
served OR is the true effect size rather an overestimate of
the true effect size) and 80% power for linkage (Support-
ing information Table 1). As expected, we found a greater
number of loci that were inconsistent with the cumulatively
rare causal variants. Specifically, we found that 30 (com-
pared to 23) of the 36 association signals are unlikely to
have been caused by causal variants with combined RAFC
< 0.005, and 14 (compared to four) of these are unlikely to
have been caused by causal variants with combined RAFC
< 0.05. For one association signal (CDKN2A/B), no plausi-
ble model could be found under this assumption due to the
large value of RAFM and strong evidence for association
but no evidence for linkage. Under either set of power as-
sumptions, our results suggest that the causal variant(s) for
many T2D loci may already have been detected by the 1000
Genomes and other sequencing projects. However, even for
these loci, resequencing may be useful to identify other in-
dependent disease variants. For the other loci for which
the summed frequency of causal variants may be < 0.005,
sequencing studies may be particularly important for vari-
ant detection, since such uncommon variants may not have
been identified in existing catalogues.
In summary, we estimate ranges of plausible genetic mod-
els based on results from association and/or linkage studies
for complex diseases. Given no or modest evidence for link-
age in a region of interest, we can estimate an upper bound
on the GRRC of potential rare or less common variants. Sim-
ilarly, in the presence of association with a common geno-
typed variant, we can estimate a lower bound on the GRR
for the causal variant. Taken together, significant evidence
for association and no or modest evidence for linkage al-
low a joint estimate of a lower bound for RAFC and upper
bound for GRRC. Our approach provides a useful starting
point for modeling genetic architecture of complex diseases
and has allowed us to identify T2D loci more likely to be
caused by common variants. The knowledge of plausible
genetic models for a given region will aid in estimating
the power of burden tests [for example Li and Leal, 2010]
for a given sample size and sequencing depth, and will al-
low more efficient design and interpretation of sequencing
studies.
WEB RESOURCES
Software to carry out this sort of analysis is avail-
able (in Stata code) at http://www.biostat.umn.edu
/∼wguan/software/.
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CC, Mirel DB, Manolio TA, Chasman DI, Boerwinkle E, Ridker PM,
Hunter DJ, Meigs JB, Lee CH, Hu FB, van Dam RM. Meta-Analysis of
Glucose and Insulin-related traits Consortium (MAGIC); Diabetes
Genetics Replication and Meta-analysis (DIAGRAM) Consortium.
2010. Genetic variants at 2q24 are associated with susceptibility to
type 2 diabetes. Hum Mol Genet 19:2706–2715.
Reich DE, Lander ES. 2001. On the allelic spectrum of human disease.
Trends Genet 17:502–510.
Risch N. 1990. Linkage strategies for genetically complex traits. II. The
power of affected relative pairs. Am J Hum Genet 46:229–241.
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP,
Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ,
Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S,
McCarroll SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè
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